Consumer Protection Act; exempt certain pharmaceutical distributors from.
Summary
House Bill 1548 amends Mississippi’s Consumer Protection Act exemption statute, Section 75-24-7, to add a new category of exempt conduct for certain pharmaceutical distributors. Under the bill, a pharmaceutical distributor would not be subject to the Consumer Protection Act when acting under an order from the U.S. Department of Justice or when responding to a “suspicious order” as defined in federal law. The bill also retains the existing exemptions for certain media publishers and for officers acting under court orders.
The practical effect is to narrow the reach of Mississippi’s consumer protection enforcement provisions in a specific drug-distribution context. By carving out these federally directed or federally defined suspicious-order responses, the bill reduces the risk that distributors could face state consumer protection liability for actions taken in compliance with federal enforcement or diversion-control requirements. The act would take effect July 1, 2025.
Impact
HB1548 would amend Section 75-24-7 of the Mississippi Code, which lists activities and actors excluded from the Consumer Protection Act, by adding pharmaceutical distributors acting under a DOJ order or in response to a suspicious order. This change would limit the application of state consumer protection law to those distributors in the specified circumstances and align the state exemption with federal drug-diversion and enforcement concepts. The bill affects pharmaceutical wholesalers/distributors and potentially state consumer-protection enforcement authorities.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the bill appears to be a targeted, technical measure with no documented opposition in the available record. Its narrow scope and incorporation of federal terminology suggest it is intended to clarify compliance obligations rather than make a broad policy change. No vote history or transcript indicates a divided sentiment.
Contention
The main policy issue is whether pharmaceutical distributors should be shielded from state consumer protection claims when they are acting in response to federal DOJ orders or suspicious-order obligations. Supporters would likely view the exemption as a necessary clarification that protects distributors complying with federal law and diversion-control duties. Potential critics could argue that the carve-out reduces state enforcement tools or could be read too broadly, but no specific objections, amendments, or recorded debate are provided in the materials.